Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Lenvatinib
Treatment for Liver cancer due to NASH
Typical Dosage: 8mg or 12mg orally once daily
Effectiveness
85%
Safety Score
40%
Clinical Trials
5
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
8mg or 12mg orally once daily
Time to Effect
1-2 months
Treatment Duration
until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$240,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$258,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$1,075,000
Cost per Remission
$12,900,000
Comparison vs Sorafenib
Cost Difference
+$200,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Lenvatinib Outcomes
for Liver cancer due to NASH
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+24%
Remission Rate
+2%
Common Side Effects
Hypertension (grade 3-4)
+24%
Fatigue
+44%
Diarrhea
+39%
Decreased appetite
+34%
Proteinuria
+26%
Palmar-plantar erythrodysesthesia
+26%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov